Navigation Links
New vaccine means bye-bye to bacteria in the lung

Pseudomonas aeruginosa is a bacterium that can cause respiratory tract infections, which can be life threatening in patients who have cystic fibrosis. It is therefore important to develop a vaccine against this pathogen. Appearing online on 1 April 2005 in advance of print publication of the May issue of The Journal of Clinical Investigation, Ronald Crystal and colleagues from Cornell University use a novel strategy to create a genetic vaccine against P. aeruginosa.

The researchers use a modified adenovirus vector vaccine expressing a region of the outer membrane of P. aeruginosa, called OprF, which had previously been recognized as a promising vaccine candidate. This region of the bacteria was expressed in the capsid area of the vector. Immunization of mice with this vaccine induced antibody production and protected the mice from exposure to a deadly dose of the bacteria. Importantly, the mice could be repeatedly given the vaccine and the immune response against P. aeruginosa was boosted. Usually, adenovirus vectors do not allow for repeated infection.

These results may be useful in the development of vaccines against bacterial pathogens. The findings that a vaccine against Pseudomonas aeruginosa is therapeutic in mice offers promise for patients with cystic fibrosis or other disorders that prevent them from effectively fighting off respiratory tract infections.


'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology , ... recognition technologies, today announced that the MegaMatcher On ... was submitted for the NIST Minutiae Interoperability ... all the mandatory steps of the evaluation protocol. ... a continuing test of fingerprint templates used to ...
(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... ... December 07, 2016 , ... Kara Dwyer Dodge grew up hearing stories of the sea ... in Scituate, Mass., found a sea turtle entangled in the lines of one of his ... a minor sensation because no one could remember ever seeing one so large so close ...
(Date:12/6/2016)... ... 06, 2016 , ... The Osteoarthritis Research Society International (OARSI) ... (FDA) to consider OA as a serious disease. As an organization of professionals ... of OA patients, many of whom may experience progressive disability and decreased quality ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... today announced it has acquired the assets of Theorem Clinical Research - ... focuses on clinical trial drug packaging, labeling, storage, reconciliation, and distribution for ...
(Date:12/6/2016)... PARK, Calif. , Dec. 6, 2016 /PRNewswire/ ... up to $150 million from the National Institutes ... Diseases and the Division of AIDS (NIAID-DAIDS) to ... and other non-vaccine pre-exposure (PreP) agents. Under the ... of preclinical product development services for candidate HIV-prevention ...
Breaking Biology Technology: